Everest Medicines Limited EBIT

Everest Medicines Limited (1952.HK) currently reports a EBIT of $-100M as of June 2026. That compares with $-390M in the prior-year period — up 74.1% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Everest Medicines Limited's EBIT history and peer comparisons.

Everest Medicines Limited's EBIT increased from $-390M to $-100M — a 74.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Everest Medicines Limited's EBIT of $-100M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Everest Medicines Limited reported $-100M in EBIT as of June 2026. That compares with $-390M in the prior-year period — up 74.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-100M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Everest Medicines Limited, and consider following 1952.HK for alerts when major investors trade the stock.